[tds_menu_login inline="yes" guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJwaG9uZSI6eyJtYXJnaW4tcmlnaHQiOiIyMCIsIm1hcmdpbi1ib3R0b20iOiIwIiwibWFyZ2luLWxlZnQiOiI2IiwiZGlzcGxheSI6IiJ9LCJwaG9uZV9tYXhfd2lkdGgiOjc2N30=" toggle_hide="eyJwaG9uZSI6InllcyJ9" ia_space="eyJwaG9uZSI6IjAifQ==" icon_size="eyJhbGwiOjI0LCJwaG9uZSI6IjIwIn0=" avatar_size="eyJwaG9uZSI6IjIwIn0=" show_menu="yes" menu_offset_top="eyJwaG9uZSI6IjE4In0=" menu_offset_horiz="eyJhbGwiOjgsInBob25lIjoiLTMifQ==" menu_width="eyJwaG9uZSI6IjE4MCJ9" menu_horiz_align="eyJhbGwiOiJjb250ZW50LWhvcml6LWxlZnQiLCJwaG9uZSI6ImNvbnRlbnQtaG9yaXotcmlnaHQifQ==" menu_uh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_gh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_ul_padd="eyJwaG9uZSI6IjhweCAxNXB4In0=" menu_ul_space="eyJwaG9uZSI6IjYifQ==" menu_ulo_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_gc_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_bg="var(--news-hub-black)" menu_shadow_shadow_size="eyJwaG9uZSI6IjAifQ==" menu_arrow_color="rgba(0,0,0,0)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="var(--news-hub-white)" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_size="eyJwaG9uZSI6IjEyIn0=" f_uh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_links_font_size="eyJwaG9uZSI6IjEyIn0=" f_links_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_links_font_family="eyJwaG9uZSI6IjMyNSJ9" f_uf_font_size="eyJwaG9uZSI6IjEyIn0=" f_uf_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uf_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_size="eyJwaG9uZSI6IjEyIn0=" f_gh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_btn1_font_family="eyJwaG9uZSI6IjMyNSJ9" f_btn1_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn1_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn2_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_family="eyJwaG9uZSI6IjMyNSJ9"]
17.9 C
New York
[tds_menu_login guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjAiLCJkaXNwbGF5IjoiIn19" toggle_txt_color="var(--news-hub-white)" menu_offset_top="eyJhbGwiOiIxOSIsImxhbmRzY2FwZSI6IjE3IiwicG9ydHJhaXQiOiIxNSJ9" menu_offset_horiz="eyJhbGwiOi02LCJsYW5kc2NhcGUiOiItMyIsInBvcnRyYWl0IjoiLTIifQ==" menu_horiz_align="content-horiz-right" menu_bg="var(--news-hub-black)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="#ffffff" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_family="325" f_uh_font_line_height="1.3" f_links_font_family="325" f_links_font_line_height="1.3" f_uf_font_line_height="1.3" f_uf_font_family="325" menu_uh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_ul_padd="eyJhbGwiOiIxOHB4IDI1cHgiLCJsYW5kc2NhcGUiOiIxNnB4IDIwcHgiLCJwb3J0cmFpdCI6IjhweCAxNXB4In0=" menu_ul_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" menu_ulo_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_shadow_shadow_size="0" menu_arrow_color="rgba(255,255,255,0)" menu_width="eyJhbGwiOiIyMjAiLCJwb3J0cmFpdCI6IjE4MCJ9" show_version="" menu_gh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_gc_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_gh_color="var(--news-hub-light-grey)" menu_gh_border_color="var(--news-hub-dark-grey)" f_gh_font_family="325" menu_gc_btn1_bg_color="var(--news-hub-accent)" menu_gc_btn1_bg_color_h="var(--news-hub-accent-hover)" menu_gc_btn2_color="var(--news-hub-accent)" menu_gc_btn2_color_h="var(--news-hub-accent-hover)" f_btn1_font_family="325" f_btn1_font_transform="uppercase" f_btn2_font_family="325" f_btn2_font_transform="uppercase" f_btn1_font_weight="700" f_btn2_font_weight="700" show_menu="yes" f_uf_font_size="eyJsYW5kc2NhcGUiOiIxMiIsInBvcnRyYWl0IjoiMTIifQ==" icon_color="var(--news-hub-white)" icon_size="eyJhbGwiOjIyLCJsYW5kc2NhcGUiOiIyMCIsInBvcnRyYWl0IjoiMTgifQ==" avatar_size="eyJhbGwiOiIyMiIsImxhbmRzY2FwZSI6IjIwIiwicG9ydHJhaXQiOiIxOCJ9" ia_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" f_toggle_font_family="325" f_toggle_font_size="eyJhbGwiOiIxNCIsImxhbmRzY2FwZSI6IjEzIiwicG9ydHJhaXQiOiIxMiJ9" logout_size="eyJhbGwiOjE0LCJsYW5kc2NhcGUiOiIxMyJ9" f_uh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_links_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_gh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ=="]
Deals

New Spigen OneTap Pro 15W 3-in-1 MagSafe charging stand just hit the $60 Amazon all-time low

9to5Toys.com - 0
The official Spigen Amazon storefront is now offering the best price yet on its new OneTap Pro (MagFit) 3-in-1 Qi2 15W Wireless Charging Stand at $59.99 shipped. Spigen is known for delivering notable value for your money, but this has to be one of the...
Deals

9to5Toys Battlestation Weekly – The best deals and new releases in PC gaming

9to5Toys.com - 0
Welcome to 9to5toys Battlestation Weekly – your go-to spot for the weekly roundup of the hottest deals and latest releases in PC gaming at a glance every Saturday morning. This week, we’re spotlighting massive discounts on a bunch of Razer gaming gear ...
gaming

Everything You Need To Know For Week 3 Of Fortnite’s Absolute Doom Season

Kotaku.com - 0
It may be Saturday, but it’s possible your week’s work has just begun. Sure, Fortnite dropped its Week 3 quests for Absolute Doom days ago, but you got a little busy, and now you’ve got some catching up to do. If Robert Downey Jr. has taught us anythin...
News

EVERSPACE 2: Titans Q&A – ROCKFISH Talks About the Upcoming DLC and More

Wccftech.com - 0
EVERSPACE 2 developer ROCKFISH Games, being headquartered in Hamburg, couldn't very well pass up on the Cologne-based Gamescom, especially since they've got the Titans DLC coming up soon. Due to launch on September 16 across all platforms (PC, PlayStation 5, and Xbox Series S|X) for a price tag of $15, this is the first story DLC for the space combat game that was fully released in 2023. I caught up with ROCKFISH Games CEO and Co-Founder Michael Schade and Communications Manager Lee Guille to learn more about EVERSPACE 2: Titans and to discuss various aspects of the industry, from their […]

9to5Toys Electrified Weekly – The best deals on EVs and environment-friendly gear

If You’ve Never Noticed The Logo On A Godiva Wrapper, Today’s NYT Connections Groups Will Be Tough

Apple Updates Its M3 MacBook Air Marketing Material, Claims It Is Up To 40 Percent Faster Than Copilot+ PCs Featuring The Snapdragon X Elite

Steam Sales, Star Wars Outlaws Guides, And More Tips And Tricks For The Week

Apple’s official 60W woven USB-C cable hits $15 Amazon all-time low, 240W model at $23

Don’t spend full price on Uber rides/food orders: Buy these discounted gift cards first from $22.50

Americans misunderstand their contribution to deteriorating environment

Leaving behind its crew, Starliner departs space station and returns to Earth

Is accidentally stumbling across the unknown a key part of science?

ASUS Intros Vivobook S 15, ProArt PZ13 Copilot+ PCs Featuring Qualcomm Snapdragon X Plus

Final Fantasy VII Remake Trilogy, Final Fantasy XVI, Pixel Remasters Are on the Docket for Xbox – Rumor

AMD Preps Replacement of AGESA With openSIL Starting Next-Gen Zen 6 “Ryzen & EPYC” Families

AMD Anti-Lag 2 SDK Now Available at GPUOpen For Direct Game Integration

AMD Ryzen 5 7600X3D Benchmarked, Faster Than Ryzen 9000 CPUs In Gaming But Slower Than 7800X3D, Consumes Around 50W in Games

Lenovo Yoga Slim 7i Aura Edition Features Fantastic Battery Life, Credits To Intel’s Lunar Lake

Analyst Shares His Final Expectation From Apple’s “Its Glowtime” iPhone 16 Launch Event

Boeing’s Starliner Succesfully Lands In White Sands New Mexico

iPhone 16 Pro To Feature The World’s Thinnest Smartphone Bezels, Down To Just 1.33mm – A Sleek 33 Percent Reduction

Apple’s Reliance On Qualcomm For Custom 5G Modems To See Downward Trend Starting Next Year, As It Plans To Complete Transition By 2027

Boeing’s NASA Astronauts Still Not Stuck In Space Even As Starliner Starts Return Journey

News

People are overdosing on off-brand weight-loss drugs, FDA warns

ArsTechnica.com - 0
Bad math and unclear directions are behind overdoses of up to 20 times the normal amount.
Read more
News

28 Million Obese Patients Are Expected To Be On GLP-1 Drugs By 2029

Wccftech.com - 0
In what substantially bolsters the veracity of the tagline that the GLP-1 anti-obesity drugs constitute one of the most compelling cases of thematic investing this decade, UBS is out today with a fresh investment note that illustrates the scale of this ongoing paradigm shift in how the healthcare industry deals with the persistent obesity pandemic. The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this hormone raises the level of insulin, which decreases blood glucose levels, and reduces the rate at which the stomach empties its contents into the small intestine, creating a […]
Read more
News

Pharma Hunger Games: Eli Lilly And Company’s GLP-1 Weight Loss Drug Is Much More Effective Than Novo Nordisk’s Says A New Study

Wccftech.com - 0
With potentially $100 billion in annual sales by 2030 up for grabs, the competition in the GLP-1 weight loss drugs space is predictably heating up, with Eli Lilly and Company (LLY) going head-to-head with the European pharma giant Novo Nordisk (NVO). A new study has upended the perceived parity between these two pharma heavy-weights, however, with Eli Lilly and Company managing to score a direct hit against Novo Nordisk. JAMA Study: Use Of Eli Lilly And Company's GLP-1 Agonist Tirzepatide Was Associated With Significantly Greater Weight Loss Than Novo Nordisk's Semaglutide For the benefit of those who might not be […]
Read more
News

New weight-loss and diabetes drugs linked to lower risk of 10 cancers

ArsTechnica.com - 0
For diabetes patients, GLP-1 drugs linked to lower cancer risks compared to insulin.
Read more
News

The GLP-1 Agonist Found In Wegovy And Ozempic Drugs Might Help In Controlling Alcohol Addiction, As Per A New Study

Wccftech.com - 0
From offering a viable solution to the obesity pandemic and its comorbidities to reducing the demand for ResMed's continuous Positive Airway Pressure (PAP) therapy devices that are used to treat the symptoms of sleep apnea, it is hardly surprising that GLP-1 drugs currently constitute one of Wall Street's biggest thematic investment ideas for the ongoing decade. Even so, researchers continue to discover new use-cases for these miracle drugs, with the latest such discovery centering on alcohol addiction control. A Primer On GLP-1 Drugs The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this […]
Read more
News

Around 42 Percent Of Those Aged 20 And Above In The US Are Obese, Yet GLP-1 Weight Loss Drugs Are Not Covered By 99...

Wccftech.com - 0
Wall Street is convinced that anti-obesity GLP-1 drugs constitute a thematic bull case, with Goldman Sachs recently pegging its estimate of annual global sales of these drugs at $130 billion by 2030. In fact, financial analysts have already begun to downgrade the long-term demand outlook for fast food giants such as McDonald's, based on assumptions that 7 percent of the total population in the US would be using GLP-1 drugs in the next 10 years, with the average caloric consumption of those users declining by around 20 percent. Yet, it is the exorbitant price tags of these drugs - at […]
Read more
News

Some Analysts Do Not Want You To Write Off Madrigal In Favor Of Eli Lilly And Company’s GLP-1 Agonist For The Treatment Of Fatty...

Wccftech.com - 0
Eli Lilly and Company (NYSE: LLY) is currently one of the two primary darlings of Wall Street when it comes to thematic investing around anti-obesity GLP-1 drugs, with Novo Nordisk constituting the other end of this emerging duopoly. Yet, it is the precise heft of these two pharma giants that continues to present emergent opportunities to their smaller counterparts, especially in obesity-related diseases such as the Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops primarily due to metabolic disorders, including […]
Read more
News

The next food marketing blitz is aimed at people on new weight-loss drugs

ArsTechnica.com - 0
Taking a weight-loss drug? Food makers have just the new food for you.
Read more
News

“Outrageously” priced weight-loss drugs could bankrupt US health care

ArsTechnica.com - 0
Prices would need to be dramatically slashed to avoid increasing the national deficit.
Read more
News

Eli Lilly and Company’s Tirzepatide GLP-1 Weight Loss Drug Is Now Poised To Shrink the Market for Breathing Machines

Wccftech.com - 0
What if a single pharmaceutical intervention regime could not only sustainably shrink your waistline but also cure your Obstructive Sleep Apnea (OSA)? This seems too good to be true. Yet, Eli Lilly and Company's (NYSE: LLY) Tirzepatide GLP-1 drug seems to have achieved just that. Eli Lilly and Company’s "Tirzepatide Led to a Mean AHI Reduction From Baseline of 62.8% Compared to 6.4% From Baseline for Placebo," as per the Results of the SURMOUNT-OSA Study 2. To wit, Eli Lilly and Company has now announced the results of two studies that investigated the impact of its Tirzepatide GLP-1 offering on […]
Read more
News

Novo Nordisk’s GLP-1 Weight Loss Drug Wegovy Is Not a Panacea for Obesity

Wccftech.com - 0
Novo Nordisk (NYSE: NVO) has added billions of dollars in market capitalization over the ongoing craze around the GLP-1 anti-obesity and anti-diabetes drugs. However, the Danish pharma giant's most recognizable weight loss drug, Wegovy, is increasingly looking like a stepping stone instead of the promised panacea for the obesity pandemic. For the benefit of those who might not be aware, the GLP-1 hormone plays an important role in suppressing hunger and regulating the production of insulin and glucose. After a meal, GLP-1 agonists raise the level of insulin, which decreases blood glucose levels. Simultaneously, these drugs reduce the speed at […]
Read more
News

Eli Lilly and Company (LLY) Hits a New All-Time High as the Craze for GLP-1 Weight Loss Drugs Goes Global

Wccftech.com - 0
The soaring demand for GLP-1 weight loss drugs is no longer just an American or European phenomenon. As these drugs proliferate through an ever-increasing segment of the globe's obese population, the GLP-1 heavyweights such as Eli Lilly and Company and Novo Nordisk continue to reap outsized rewards. The Ozempic effect: According to Goldman Sachs, the reduction in obesity-related health concerns could boost U.S. GDP by 0.4% to 1% with widespread uptake of weight-loss medications — Julian Klymochko (@JulianKlymochko) March 3, 2024 GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Eli […]
Read more

Tag: GLP-1

Galaxy S25 Ultra Render Gets Teased By An Incredibly Reliable Leakster, But Image Is Kept Blurred Until Donation Goal Has Been Reached

News
Samsung has been reported on multiple occasions to introduce a design change with the Galaxy S25 Ultra launch, with the flagship said to feature rounded corners instead of sharp ones, resembling the company’s Galaxy Note 7. However, it is one thing to check out an artist’s impression of the smartphone and another to view an actual render, and we are happy to mention that an official image has come out, but there is a catch. The notable leakster responsible for showcasing the Galaxy S25 Ultra to his fans has blurred it out unless his financial target is met. Donation goal from […]

Star Wars Outlaws Is Simultaneously Astounding And Busted, The Minecraft Movie Knows Its Audience, And More Of The Week’s Takes

gaming
This week saw the release of Astro Bot, a delightful game that pays tribute to the rich history of PlayStation. It also, inadvertently, highlights the dearth of new games and franchises really worth celebrating from the PS5 era. Also, Star Wars Outlaws...

People are overdosing on off-brand weight-loss drugs, FDA warns

News
Bad math and unclear directions are behind overdoses of up to 20 times the normal amount.

28 Million Obese Patients Are Expected To Be On GLP-1 Drugs By 2029

News
In what substantially bolsters the veracity of the tagline that the GLP-1 anti-obesity drugs constitute one of the most compelling cases of thematic investing this decade, UBS is out today with a fresh investment note that illustrates the scale of this ongoing paradigm shift in how the healthcare industry deals with the persistent obesity pandemic. The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this hormone raises the level of insulin, which decreases blood glucose levels, and reduces the rate at which the stomach empties its contents into the small intestine, creating a […]

Pharma Hunger Games: Eli Lilly And Company’s GLP-1 Weight Loss Drug Is Much More Effective Than Novo Nordisk’s Says A New Study

News
With potentially $100 billion in annual sales by 2030 up for grabs, the competition in the GLP-1 weight loss drugs space is predictably heating up, with Eli Lilly and Company (LLY) going head-to-head with the European pharma giant Novo Nordisk (NVO). A new study has upended the perceived parity between these two pharma heavy-weights, however, with Eli Lilly and Company managing to score a direct hit against Novo Nordisk. JAMA Study: Use Of Eli Lilly And Company's GLP-1 Agonist Tirzepatide Was Associated With Significantly Greater Weight Loss Than Novo Nordisk's Semaglutide For the benefit of those who might not be […]

New weight-loss and diabetes drugs linked to lower risk of 10 cancers

News
For diabetes patients, GLP-1 drugs linked to lower cancer risks compared to insulin.

The GLP-1 Agonist Found In Wegovy And Ozempic Drugs Might Help In Controlling Alcohol Addiction, As Per A New Study

News
From offering a viable solution to the obesity pandemic and its comorbidities to reducing the demand for ResMed's continuous Positive Airway Pressure (PAP) therapy devices that are used to treat the symptoms of sleep apnea, it is hardly surprising that GLP-1 drugs currently constitute one of Wall Street's biggest thematic investment ideas for the ongoing decade. Even so, researchers continue to discover new use-cases for these miracle drugs, with the latest such discovery centering on alcohol addiction control. A Primer On GLP-1 Drugs The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this […]

Around 42 Percent Of Those Aged 20 And Above In The US Are Obese, Yet GLP-1 Weight Loss Drugs Are Not Covered By 99...

News
Wall Street is convinced that anti-obesity GLP-1 drugs constitute a thematic bull case, with Goldman Sachs recently pegging its estimate of annual global sales of these drugs at $130 billion by 2030. In fact, financial analysts have already begun to downgrade the long-term demand outlook for fast food giants such as McDonald's, based on assumptions that 7 percent of the total population in the US would be using GLP-1 drugs in the next 10 years, with the average caloric consumption of those users declining by around 20 percent. Yet, it is the exorbitant price tags of these drugs - at […]

Some Analysts Do Not Want You To Write Off Madrigal In Favor Of Eli Lilly And Company’s GLP-1 Agonist For The Treatment Of Fatty...

News
Eli Lilly and Company (NYSE: LLY) is currently one of the two primary darlings of Wall Street when it comes to thematic investing around anti-obesity GLP-1 drugs, with Novo Nordisk constituting the other end of this emerging duopoly. Yet, it is the precise heft of these two pharma giants that continues to present emergent opportunities to their smaller counterparts, especially in obesity-related diseases such as the Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops primarily due to metabolic disorders, including […]

The next food marketing blitz is aimed at people on new weight-loss drugs

News
Taking a weight-loss drug? Food makers have just the new food for you.

“Outrageously” priced weight-loss drugs could bankrupt US health care

News
Prices would need to be dramatically slashed to avoid increasing the national deficit.

Eli Lilly and Company’s Tirzepatide GLP-1 Weight Loss Drug Is Now Poised To Shrink the Market for Breathing Machines

News
What if a single pharmaceutical intervention regime could not only sustainably shrink your waistline but also cure your Obstructive Sleep Apnea (OSA)? This seems too good to be true. Yet, Eli Lilly and Company's (NYSE: LLY) Tirzepatide GLP-1 drug seems to have achieved just that. Eli Lilly and Company’s "Tirzepatide Led to a Mean AHI Reduction From Baseline of 62.8% Compared to 6.4% From Baseline for Placebo," as per the Results of the SURMOUNT-OSA Study 2. To wit, Eli Lilly and Company has now announced the results of two studies that investigated the impact of its Tirzepatide GLP-1 offering on […]

Novo Nordisk’s GLP-1 Weight Loss Drug Wegovy Is Not a Panacea for Obesity

News
Novo Nordisk (NYSE: NVO) has added billions of dollars in market capitalization over the ongoing craze around the GLP-1 anti-obesity and anti-diabetes drugs. However, the Danish pharma giant's most recognizable weight loss drug, Wegovy, is increasingly looking like a stepping stone instead of the promised panacea for the obesity pandemic. For the benefit of those who might not be aware, the GLP-1 hormone plays an important role in suppressing hunger and regulating the production of insulin and glucose. After a meal, GLP-1 agonists raise the level of insulin, which decreases blood glucose levels. Simultaneously, these drugs reduce the speed at […]

Eli Lilly and Company (LLY) Hits a New All-Time High as the Craze for GLP-1 Weight Loss Drugs Goes Global

News
The soaring demand for GLP-1 weight loss drugs is no longer just an American or European phenomenon. As these drugs proliferate through an ever-increasing segment of the globe's obese population, the GLP-1 heavyweights such as Eli Lilly and Company and Novo Nordisk continue to reap outsized rewards. The Ozempic effect: According to Goldman Sachs, the reduction in obesity-related health concerns could boost U.S. GDP by 0.4% to 1% with widespread uptake of weight-loss medications — Julian Klymochko (@JulianKlymochko) March 3, 2024 GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Eli […]
123Page 1 of 3

Recent articles

spot_img

©Patti.tech 2022